SIFROL - SIFROL - CT 3918 - English version

Description

Introduction SIFROL 0.088 mg unscored tablets, B/30 - CIP : 363 467.9 SIFROL 0.18 mg scored tablets, B/30 - CIP : 363 469.1 and B/100 - CIP : 363 471.6 SIFROL 0.35 mg scored tablets, B/30 - CIP : 363 472.2 SIFROL 0.7 mg scored tablets, B/30 - CIP : 363 474.5 and B/100 - CIP : 363 475.1 Posted on Jun 24 2009 Active substance (DCI) pramipexole ATC Code N04BC05 Laboratory / Manufacturer BOEHRINGER INGELHEIM SIFROL 0.088 mg unscored tablets, B/30 - CIP : 363 467.9 SIFROL 0.18 mg scored tablets, B/30 - CIP : 363 469.1 and B/100 - CIP : 363 471.6 SIFROL 0.35 mg scored tablets, B/30 - CIP : 363 472.2 SIFROL 0.7 mg scored tablets, B/30 - CIP : 363 474.5 and B/100 - CIP : 363 475.1 Posted on Jun 24 2009

Subjects

• Documents
• Savoirs
• Medicine
• Gériatrie
• Maladie neurodégénérative
• Médecine

Informations

• Published by: haute-autorite-sante-troubles-mentaux-et-comportementaux
• Published: 28 February 2007
• Reads: 27
• Language: English

Exrait

          The legally binding text is the original French version   TRANSPARENCY COMMITTEE   OPINION   28 February 2007         SIFROL 0.088 mg unscored tablets, B/30 - cip 363 467.9 SIFROL 0.18 mg scored tablets, B/30 - cip 363 469.1 and B/100 - cip 363 471.6 SIFROL 0.35 mg scored tablets, B/30 - cip 363 472.2 SIFROL 0.7 mg scored tablets, B/30 - cip 363 474.5 and B/100 - cip 363 475.1     Applicant : BOEHRINGER INGELHEIM   Pramipexole   List I   Marketing authorisation dates (centralised procedure): 14 October 1997, 6 April 2006 (extension of indication), 7 August 2006.     Reason for request: Inclusion on the list of medicines reimbursed by National Insurance and approved for use in hospital in the indication: symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt)                                               Health Technology Assessment Division  

 

1